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Effect of pravastatin on type IV collagen secretion and mesan- and/or its metabolite(s) play a critical role in the prolifer-
gial cell proliferation. ation of mammalian cells. It has also been reported that
Background. The mevalonate pathway is important for the treatment with 3-hydroxy-3-methylglutaryl-coenzyme Abiosynthesis of isoprenoids such as geranylgeranylpyrophos-
(HMG-CoA) reductase inhibitor ameliorates glomerularphate (GGPP) and farnesylpyrophosphate (FPP) as well as
injury in several experimental models of progressive glo-cholesterol. It has been reported that treatment with 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor merular diseases [2]. Besides its ability to lower circulat-
ameliorates glomerular injury in several experimental models ing lipid concentrations, it has been reported that metab-
of progressive glomerular disease. The present investigation olites of the mevalonate pathway play an important rolewas performed to elucidate the role of mevalonate metabolites
in mesangial cell proliferation and apoptosis [3, 4]. How-in mesangial cell proliferation and extracellular matrix accumu-
ever, little is known about the involvement of the meva-lation.
Method. Cycling or quiescent human mesangial cells were lonate cascade in the metabolism of extracellular matrix.
incubated in RPMI1640 containing 10% heat-inactivated fetal Furthermore, it is still unclear which metabolites of the
calf serum (FCS) in the absence or presence of pravastatin, an mevalonate pathway are essential for the proliferationinhibitor of HMG-CoA reductase, and mevalonate metabo-
of mesangial cells. The present investigation was per-lites. Type IV collagen secretion and mRNA expression, [3H]-
formed to gain further insight into the role of the mevalo-thymidine incorporation was measured. Cell cycle phases were
monitored by flow cytometry. nate cascade in human mesangial cell proliferation and
Results. Pravastatin inhibited FCS-stimulated type IV colla- extracellular matrix accumulation.
gen secretion (IC50 5 210 mm) and mRNA expression. Prava-
statin also inhibited FCS-stimulated [3H]-thymidine incorpora-
tion (IC50 5 430 mm). Analysis with flow cytometry revealed METHODS
that pravastatin inhibited G1 to S phase transition of FCS-
Pravastatin, an inhibitor of HMG-CoA reductase, wasstimulated mesangial cells. Mevalonate reversed these inhibi-
tory effects of pravastatin completely. Among two major me- kindly provided from Sankyo Pharmaceutical Co., Ltd.
tabolites of mevalonate, GGPP and FPP, only GGPP reversed (Tokyo, Japan). Liposomes containing GGPP and FPP
pravastatin-induced inhibition of type IV collagen secretion, were prepared as reported previously [5]. Type IV colla-
DNA synthesis and G1 to S phase progression.
gen secretion was measured as follows. When cellsConclusion. The present results suggest that GGPP plays a
reached confluent, they were incubated for another 48critical role in the type IV collagen secretion and G1 to S phase
transition in FCS-stimulated human mesangial cells. hours in RPMI1640 containing 10% heat-inactivated fe-
tal calf serum (FCS) in the absence or presence of prava-
statin (0 to 1200 mm), mevalonate (0.5 mg/ml), liposomes
The mevalonate pathway is important for the biosyn- containing GGPP (2.5 to 10 mm) and FPP (10 mm). After
thesis of isoprenoids such as geranylgeranylpyrophos- 48 hours, type IV collagen secreted into culture media
phate (GGPP) and farnesylpyrophosphate (FPP) as well was measured by enzyme immunoassay. Data are ex-
as cholesterol [1]. It has been revealed that mevalonate pressed as percentage of positive control (type IV colla-
gen secretion from cells incubated in 10% FCS). Gene
expression was examined as follows. When cells reachedKey words: HMG-CoA, mevalonate, GGPP, farneslypyrophosphate,
collagen, cell cycle. confluent, culture media were changed to RPMI1640
containing 10% heat-inactivated FCS and pravastatin 1999 by the International Society of Nephrology
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Fig. 1. (A) Effect of pravastatin and mevalo-
nate metabolites on type IV collagen secre-
tion. Data represent mean 6 sd of 4 separate
experiments each done in triplicate (**P ,
0.01). (B) Effect of pravastatin and mevalo-
nate metabolites on type IV collagen gene
expression. Total RNA was extracted at: [lane
1] 0 hours, [lane 2] 12 hours, [lane 3] 24 hours,
[lane 4] 48 hours, [lane 5] 72 hours after pra-
vastatin-treatment was initiated. [lane 6] Total
RNA was extracted 48 hours after pravastatin
and mevalonate treatment was initiated.
(1200 mm). Total RNA from the cells was isolated at [3H]-thymidine incorporation was counted. Data are ex-
pressed as percentage of positive control ([3H]-thymidinevarious times after initiation of pravastatin treatment.
Type IV collagen cDNA probe was kindly provided by incorporation into 10% FCS-stimulated cells). Analysis
of variance was performed in evaluation of the data.Dr. S. Kaname (Tokyo University, Tokyo, Japan). DNA
synthesis was measured as follows. Subconfluent human
mesangial cells were made quiescent by placing them in
RESULTS
serum free RPMI1640 medium for 48 hours. Then, cells
Effect of pravastatin and mevalonate metabolites onwere stimulated by 10% FCS for 24 hours. Pravastatin
type IV collagen secretion and gene expression(100 to 1200 mm), mevalonate (0.5 mg/ml), liposomes
containing GGPP (10 mm) and FPP (10 mm) were added Pravastatin caused a dose-dependent suppression in
type IV collagen secretion (IC50 5 210 mm). This inhibi-into culture media when serum-stimulation was initiated.
During the last four hours of the incubation period, the tion was fully recovered by the addition of mevalonate
(0.5 mg/ml; data not shown). As shown in Figure 1A,cells were pulsed with [3H]-thymidine (1 mCi/well) and
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the mevalonate cascade is involved in the regulation of
secretion of extracellular matrix. These inhibitory effects
of pravastatin were completely reversed by mevalonate.
Mevalonate acts as a isoprenyl precursor for GGPP and
FPP. The inhibitory effects of pravastatin on type IV
collagen secretion, DNA synthesis and G1 to S phase
transition were reversed by GGPP, but not by FPP.
These results indicate that GGPP plays a critical role in
type IV collagen expression and proliferation of mesan-
gial cells.
A number of small G-proteins, such as Ras, Rho and
Rac, have been shown to be involved in the G1 to S
phase transition of the cell cycle progression. As these
Fig. 2. Effect of pravastatin and mevalonate metabolites on DNA syn- proteins require prenylation for their proper function,
thesis in fetal calf serum (FCS)-stimulated human mesangial cells. Lanes it is suggested that the inhibitory effect of HMG-CoAare: [1] 0.5% bovine serum albumin (BSA); [2] 10% FCS; [3]
reductase inhibitor on cell proliferation is attributed to10% FCS 1 pravastatin (1200 mm); [4–6] 10% FCS 1 pravastatin
(1200 mm) 1 liposomes containing [4] vehicle [5], GGPP (10 mm) [6], the inhibition of prenylation of these small G-proteins
FPP (10 mm). Data are expressed as percentage of positive control
[6, 7]. Hirai and Noguchi reported that geranylgeranyla-([3H]-thymidine incorporation into 10% FCS-stimulated cells). Data
represent mean 6 sd of 5 separate experiments each done in duplicate tion of Rho small GTPase(s) is essential for the cell cycle
(**P , 0.01). progression in rat thyroid FRTL-5 cells [5, 8]. Ghosh et
al reported that Rho A accumulated in the cytosol in
lovastatin-treated mesangial cells, which suggests that
Rho A requires to be prenylated for its activation [4].the inhibitory effect of pravastatin (1200 mm) on type
Therefore, Rho small GTPase(s) can be good candidateIV collagen secretion was reversed by the addition of
for the geranylgeranylated protein(s) that is importantGGPP. On the other hand, FPP had little effect. As
for cell cycle progression. On the other hand, the preciseshown in Figure 1B, treatment of human mesangial cells
mechanism by which the mevalonate cascade influenceswith pravastatin (1200 mm) reduced type IV collagen
the metabolism of extracellular matrix is not fully under-mRNA expression time dependently. This inhibition was
stood and should be elucidated in future.also reversed by mevalonate (0.5 mg/ml).
In conclusion, the present results demonstrate that in
human mesangial cells, the intrinsic mevalonate cascadeEffect of pravastatin on DNA synthesis and cell
plays critical role in type IV collagen gene expression,cycle progression
secretion and the transition from G1 to S phase, andPravastatin caused a dose-dependent suppression in
that among mevalonate metabolites, GGPP is essentialFCS-stimulated DNA synthesis in mesangial cells
for these functions. It would be important to determine(IC50 5 430 mm). This inhibition was fully recovered by
which proteins are geranylgeranylated and essential forthe addition of mevalonate (0.5 mg/ml; data not shown).
these functions of human mesangial cells.As shown in Figure 2, GGPP reversed the inhibitory
effect of pravastatin on DNA synthesis from 23.1% to
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